Radical therapeutic agent for keloid and hypertrophic scar

A technology for hypertrophic scars and keloids, which is applied in the field of elastic fiber formation accelerators and radical therapeutic drugs for keloids and/or hypertrophic scars, and can solve problems such as the inability to develop radical therapeutic effects on keloids

Inactive Publication Date: 2011-02-09
SEIKAGAKU KOGYO CO LTD +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0028] In animals other than humans, keloids do not occur and can heal, so as mentioned above, it is currently impossible to develop a test system that can evaluate the effect of radical treatment on keloids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Radical therapeutic agent for keloid and hypertrophic scar
  • Radical therapeutic agent for keloid and hypertrophic scar
  • Radical therapeutic agent for keloid and hypertrophic scar

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0098] Hereinafter, the present invention will be described in more detail based on examples, but the present invention is not limited by these examples.

reference example 1

[0099] [Reference Example 1] Observation of keloid lesion site and normal skin site

[0100] Human tissue samples containing keloid lesions and normal skin parts were removed from keloid patients as tissue materials. The samples were fixed with 4% paraformaldehyde at 4°C for 24 hours, and then embedded in paraffin to prepare paraffin blocks and 3 μm paraffin sections. After deparaffinization, hematoxylin-eosin (HE) staining and elastic van Gieson (EVG) staining were performed to prepare the specimens. A microscope is used to look at the keloid tissue and normal skin tissue.

reference example 2

[0101] The result is as figure 1 shown. The part marked with a line is the keloid lesion site, and the adjacent part is the normal skin site. By EVG staining, the elastic fiber structure stained black (arrow) can be confirmed in the normal skin site other than the keloid lesion site, and the majority of the keloid lesion site can be seen to be transparent, and the lack of elastic fiber structure formation can be confirmed. [Reference Example 2] mRNA Expression of Elastic Fiber Components in Keloid Lesion Tissue and Normal Skin Tissue

[0102] Keloid lesions (4 persons) and normal skin tissues (3 persons) were removed from human samples as tissue materials. Total RNA was extracted from keloid tissue and normal skin tissue using RNeasy Plus kit (manufactured by Keygen Co., Ltd.). cDNA was synthesized from 1 μg of total RNA using an advantage RT for PCR kit (manufactured by Nippon Beckton Ditsukinn Co., Ltd.), and the expression of mRNA of seven proteins constituting elastic f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is an effective therapeutic agent for keloid and / or hypertrophic scar. Specifically disclosed are: an elastic fiber-regenerating agent, which comprises chondroitinase ABC derived from Proteus vulgaris; and a therapeutic agent for keloid and / or hypertrophic scar, which comprises the regenerating agent as an active ingredient.

Description

technical field [0001] The present invention relates to an agent for promoting the formation of elastic fibers and a medicine for the radical treatment of keloid and / or hypertrophic scar. Background technique [0002] The abbreviated symbols used in this manual are as follows. [0003] GAG: Glycosaminoglycan [0004] CS: Chondroitin Sulfate [0005] CS-A: Chondroitin Sulfate A [0006] CS-B: Chondroitin Sulfate B [0007] CS-C: Chondroitin Sulfate C [0008] CSPG: Chondroitin Sulfate Proteoglycan [0009] GAGase: Glycosaminoglycan decomposing enzyme [0010] CSase: Chondroitinase (chondroitin sulfate decomposing enzyme) [0011] CSase-ABC: Chondroitinase ABC [0012] CSase-B: Chondroitinase B [0013] CSase-AC: Chondroitinase AC [0014] Hypertrophic scars or keloids can be understood as the wounds on the skin that cannot regenerate the original normal tissue during the healing process, but form fibrous tissue called "scar tissue", that is, the so-called wound heal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P17/02A61K38/51
CPCC12N9/88A61K38/00C07K14/24A61P17/02
Inventor 铃木茂彦内藤素子池田实香
Owner SEIKAGAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap